Belgian Luxury Stock News

Anheuser-Busch InBev (ENXTBR:ABI) posted a net profit margin of 12.2% for the most recent period, a jump from last year’s 9.9%. Over the past five years, the company has averaged 24.5% annual earnings growth, with current-year earnings up 20%. Although this is not as rapid as previous years, it is still growing. With analysts forecasting another 10.03% per year in earnings growth and the stock trading well below consensus fair value estimates, investors are likely to see the current...

argenx (ENXTBR:ARGX) has achieved a notable turnaround to profitability over the past year, posting high-quality earnings and sustaining a five-year annual earnings growth rate of 52.7%. Looking ahead, consensus forecasts point to annual earnings growth of 28%, outpacing the Belgian market’s 15.6% projection, while revenue is also expected to rise by 18.5% per year compared to an 8.4% market average. Investors are weighing these strong growth figures and recent profitability against...

Aedifica announced in late October that it has raised its 2025 earnings guidance and reported solid nine-month results, with sales reaching €271.79 million and net income of €194.12 million. A key highlight is the 3.1% like-for-like rental income growth, reflecting improved operational momentum alongside continued asset rotation and new investment initiatives. We'll explore how the uplifted earnings forecast reinforces Aedifica's investment narrative and signals continued operating momentum...

Cenergy Holdings (ENXTBR:CENER) has quietly posted some eye-catching returns over the past year, with shares climbing more than 70%. This strong momentum puts the stock in focus for investors who want to understand what is driving its performance. See our latest analysis for Cenergy Holdings. Cenergy Holdings’ 71% total shareholder return over the past year stands out against a backdrop of accelerating momentum. The company has also seen a 36.7% share price return in the last 90 days and...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

In recent announcements, Cmb.Tech NV reported the delivery of five newbuilding vessels across several categories and revealed the sale of multiple ships, generating significant capital gains set for the third and fourth quarters of 2025. These developments highlight how Cmb.Tech is actively renewing its fleet and managing assets to support operational improvements and future revenue stability. To understand the impact on Cmb.Tech's investment narrative, we will examine how these fleet...

Aedifica (ENXTBR:AED) posted a net profit margin of 62.1%, doubling last year’s margin of 31.1%. EPS growth soared by 115.1% as the company rebounded from a 5-year annual decline of 10.7%. Revenue is forecast to grow 3% annually, below the Belgian market's 8.4%, but earnings are projected to climb 18.8% per year, outpacing the market's 15.6% rate. Positive investor sentiment is likely to focus on the strong momentum in profitability and attractive valuation metrics, even as financial...

Nyxoah SA ( EBR:NYXH ) shareholders should be happy to see the share price up 14% in the last month. But that doesn't...

Cmb.Tech (ENXTBR:CMBT) stock is catching investors’ attention today as recent trading patterns point to shifts in sentiment. Shares have seen mixed returns lately, bringing valuation and future prospects into sharper focus for the market. See our latest analysis for Cmb.Tech. While Cmb.Tech’s share price ticked higher over the past quarter, overall momentum has cooled, with a recent one-year total shareholder return of -41.5%. Investors seem to be weighing past volatility against the...

As the European market navigates a mixed landscape, with the pan-European STOXX Europe 600 Index inching higher amid dovish signals from the U.S. Federal Reserve and easing trade tensions, investors are keenly observing economic indicators like industrial production and labor market dynamics. In this environment, identifying promising small-cap stocks that can withstand volatility and capitalize on emerging opportunities is crucial for enhancing portfolio resilience.

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Key Insights Institutions' substantial holdings in Azelis Group implies that they have significant influence over the...

Warehouses De Pauw (WDP) recently reported earnings for the nine months ended September 30, 2025, posting sales of €335.6 million, up from €284.28 million a year earlier, but net income fell to €246.68 million compared to €306.32 million in the prior period. In addition, Clifford Chance announced it advised on WDP’s inaugural €500 million green senior unsecured bond issuance under its EMTN programme, following a Moody’s upgrade of WDP’s long-term issuer rating to A3 with a stable...

On October 13, 2025, UCB announced that Neurology had published favorable results from a multicenter retrospective chart review study of its investigational pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 deficiency (TK2d), showing that 29% (6 out of 21) of treated individuals experienced reduced need for ventilatory support and most adverse events were mild. An interesting aspect of the study is the potential clinical impact on this rare neuromuscular...

Warehouses De Pauw (ENXTBR:WDP) just posted results for the nine months ending September 2025. Sales climbed compared to last year, while net income and earnings per share slipped during the same stretch. See our latest analysis for Warehouses De Pauw. Warehouses De Pauw’s 8.5% share price return over the last 90 days suggests growing optimism, even though the total shareholder return for the past year has been a more modest 2.1%. In the broader context, recent gains appear to reflect renewed...

UCB (ENXTBR:UCB) just shared results from a multicenter study published in Neurology, highlighting that a new investigational therapy for TK2 deficiency showed some treated patients needed less ventilatory support, with mostly mild side effects. See our latest analysis for UCB. Despite some recent pullbacks, UCB’s share price has surged with a 22.5% gain over the past month and a remarkable 42.2% in the last 90 days. Momentum appears to be on the upswing, and when you look at the long game,...

argenx SE recently presented new data for VYVGART® and its efgartigimod pipeline at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco. These clinical updates, which include pivotal trial and real-world data across multiple patient subgroups, highlight advances in treating generalized myasthenia gravis and support ongoing innovation in rare neuromuscular...

D'Ieteren Group SA ( EBR:DIE ), is not the largest company out there, but it saw significant share price movement...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But its...

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 15x, you may consider Elia...

UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...

Umicore SA ( EBR:UMI ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...